Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tetrandrine(μM): 6 6 6 6 Sorafenib(μM): 0 3 4 5 Tetrandrine(μM): 0 4 5 6 Sorafenib(μM): 4 4 4 4 A B S 1 Cell viability for the combination of sorafenib.

Published byJack Eaton Modified over 9 years ago

Similar presentations

Presentation on theme: "Tetrandrine(μM): 6 6 6 6 Sorafenib(μM): 0 3 4 5 Tetrandrine(μM): 0 4 5 6 Sorafenib(μM): 4 4 4 4 A B S 1 Cell viability for the combination of sorafenib."— Presentation transcript:

1 Tetrandrine(μM): 6 6 6 6 Sorafenib(μM): 0 3 4 5 Tetrandrine(μM): 0 4 5 6 Sorafenib(μM): 4 4 4 4 A B S 1 Cell viability for the combination of sorafenib and tetrandrine in various concentrations

2 BEL7402 S 2 Dose-response curves and combination index values (CI ﹤ 1 ) showed the synergistic effect of combination with sorafenib and tetrandrine was existed

3 Cell cycle for combination of sorafenib and tetrandrine showed no significant alteration S 3 HCT116 BEL7402 ConTet+BayTetBay

4 Sor － ＋ － ＋ Tet － － ＋ ＋ * Activation of caspase-3 and caspase-9 in BEL7402 cells was determined after treatment with sorafenib and/or tetrandrine for 24 h S 4

5 S 5 The body weights of nude mice bearing established HCT116 tumor xenografts

6 GAPDH BEL7402HCT116 Sor － ＋ － ＋ － ＋ － ＋ Tet － － ＋ ＋ － － ＋ ＋ LC3- Ⅰ LC3- Ⅱ Cell viability could not be rescued by the autophagy inhibitor 3-methyladenine (3-MA) or chloroquine (CQ) BEL7402 Cell Viability(%) Sor: － － ＋ ＋ － － ＋ ＋ Tet : － ＋ － ＋ － ＋ － ＋ Inhibitor: － － － － ＋ ＋ ＋ ＋ S 6 A B

7 TET: － － ＋ ＋ PD: － ＋ － ＋ TET : － － ＋ ＋ PD : － ＋ － ＋ TET : － － ＋ ＋ SB : － ＋ － ＋ TET : － － ＋ ＋ SB : － ＋ － ＋ S 7 A B Cell viability for combination of tetrandrine and PD98059 (A) or SB 203580 (B)

8 A HCT116 WT Bax -/- Bax GAPDH S 8 B C WT Bax - /- WT+S+T Intracellular ROS Bax - /- +S+T WTBax -/- Sorafenib : － － ＋ ＋ Tetrandrine : － － ＋ ＋ ** HCT116 cells with Bax-/- were not sensitive to the combination treatment with sorafenib and tetrandrine as the HCT116 wild type cells

Download ppt "Tetrandrine(μM): 6 6 6 6 Sorafenib(μM): 0 3 4 5 Tetrandrine(μM): 0 4 5 6 Sorafenib(μM): 4 4 4 4 A B S 1 Cell viability for the combination of sorafenib."

Similar presentations

Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.

Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.
BEL7402Huh7 C Tet Rapa C Tet Rapa LC3-II LC3-I GAPDH Figure S1 Detecting Tetrandrine-induced autophagy in Huh7 and BEL7402 cell lines. Rapamycin treatment.

BEL7402Huh7 C Tet Rapa C Tet Rapa LC3-II LC3-I GAPDH Figure S1 Detecting Tetrandrine-induced autophagy in Huh7 and BEL7402 cell lines. Rapamycin treatment.
By: LaShanale Wallace.  Introduction: What is Autophagy?  Objective  Specific examples  Conclusion.

By: LaShanale Wallace.  Introduction: What is Autophagy?  Objective  Specific examples  Conclusion.
Supplementary Figure 1: Silibinin has no considerable radiosensitizer effect on radioresponsive prostate cancer 22RV1 cells. (A) Effect of IR and SB on.

Supplementary Figure 1: Silibinin has no considerable radiosensitizer effect on radioresponsive prostate cancer 22RV1 cells. (A) Effect of IR and SB on.
SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and.

SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and.
A B Supplementary Figure 1. (A) Western blots were performed on the three cell lines to analyze the levels of p-ERK, which is a key protein involved in.

A B Supplementary Figure 1. (A) Western blots were performed on the three cell lines to analyze the levels of p-ERK, which is a key protein involved in.
Laboratory of Dr. Dominic Smiraglia Roswell Park Cancer Institute

Laboratory of Dr. Dominic Smiraglia Roswell Park Cancer Institute
 Chemotherapy is a common strategy used to kill cancer cells.  However toxicity of chemotherapy drugs to normal cells limits their application.

 Chemotherapy is a common strategy used to kill cancer cells.  However toxicity of chemotherapy drugs to normal cells limits their application.
Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model  Jie Li, Ni Hou, Ahmad Faried, Soichi Tsutsumi,

Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model  Jie Li, Ni Hou, Ahmad Faried, Soichi Tsutsumi,
Volume 358, Issue 2, Pages (March 2015)

Volume 358, Issue 2, Pages (March 2015)
Fig. 1. Effects of letrozole (Let; 10 μg/day) and tamoxifen (Tam; 100 μg/day) and their combined or alternating treatment on the growth of MCF-7Ca breast.

Fig. 1. Effects of letrozole (Let; 10 μg/day) and tamoxifen (Tam; 100 μg/day) and their combined or alternating treatment on the growth of MCF-7Ca breast.
Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.

Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.
Fig. 1. APG increased the sensitivity of BEL-7402/ADM cells to ADM

Fig. 1. APG increased the sensitivity of BEL-7402/ADM cells to ADM
Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.
Volume 21, Issue 7, Pages (July 2013)

Volume 21, Issue 7, Pages (July 2013)
Volume 21, Issue 12, Pages (December 2017)

Volume 21, Issue 12, Pages (December 2017)
Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Similar presentations

Ads by Google